-
Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection.
J Immunol. 2003 Jul 1;171(1):477-88
PMID: 12817033
-
Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection.
J Virol. 2004 Jan;78(2):630-41
PMID: 14694094
-
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.
J Virol. 2003 Oct;77(20):10900-9
PMID: 14512540
-
HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.
J Exp Med. 2003 Dec 15;198(12):1909-22
PMID: 14676302
-
Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.
Blood. 2004 Feb 1;103(3):966-72
PMID: 12958069
-
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87
PMID: 15097300
-
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
J Virol. 1994 Jul;68(7):4650-5
PMID: 8207839
-
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
J Virol. 1994 Sep;68(9):6103-10
PMID: 8057491
-
HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial.
AIDS. 1994 Oct;8(10):1429-35
PMID: 7818813
-
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
Science. 1997 Nov 21;278(5342):1447-50
PMID: 9367954
-
In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
Clin Diagn Lab Immunol. 1998 May;5(3):308-12
PMID: 9605982
-
Acute human immunodeficiency virus type 1 infection.
N Engl J Med. 1998 Jul 2;339(1):33-9
PMID: 9647878
-
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
Science. 1999 Feb 5;283(5403):857-60
PMID: 9933172
-
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection.
J Virol. 2003 Jun;77(12):6867-78
PMID: 12768006
-
Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
J Infect Dis. 2003 Mar 1;187(5):748-57
PMID: 12599048
-
HIV-specific immunity during structured antiviral drug treatment interruption.
Vaccine. 2003 Mar 7;21(11-12):1066-71
PMID: 12559781
-
Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.
J Virol. 2003 Feb;77(3):2081-92
PMID: 12525643
-
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.
Nat Immunol. 2002 Nov;3(11):1061-8
PMID: 12368910
-
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
J Infect Dis. 2002 Jan 1;185(1):61-8
PMID: 11756982
-
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.
J Virol. 2001 Dec;75(24):11983-91
PMID: 11711588
-
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
J Exp Med. 1999 Mar 15;189(6):991-8
PMID: 10075982
-
Vpr is preferentially targeted by CTL during HIV-1 infection.
J Immunol. 2001 Sep 1;167(5):2743-52
PMID: 11509618
-
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.
J Exp Med. 2001 Jan 15;193(2):169-80
PMID: 11148221
-
Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.
AIDS. 2000 Nov 10;14(16):2475-8
PMID: 11101057
-
Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection.
Blood. 2000 Nov 1;96(9):3094-101
PMID: 11049989
-
Immune control of HIV-1 after early treatment of acute infection.
Nature. 2000 Sep 28;407(6803):523-6
PMID: 11029005
-
HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):264-9
PMID: 10969351
-
Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.
J Clin Invest. 1999 Nov;104(10):1431-9
PMID: 10562305
-
Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals.
J Virol. 2001 Nov;75(22):10843-55
PMID: 11602725
-
Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
AIDS. 2003 May 23;17(8):1121-6
PMID: 12819512